6-甲氧基-3-吡啶甲脒 | 736912-54-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 6-甲氧基-3-吡啶甲脒
• 英文名称: 6-methoxynicotinimidamide
• 英文别名: JBSNF-000408；6-methoxy-nicotinamidine；6-Methoxy-nicotinamidin；6-methoxypyridine-3-carboxamidine；6-methoxy-3-Pyridinecarboximidamide；6-methoxypyridine-3-carboximidamide
• CAS: 736912-54-2
• 化学式: C₇H₉N₃O
• 分子量: 151.168
• InChiKey: FVGLKDNCBWAFST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  72
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-甲氧基-3-吡啶甲脒 、 2-(2,6-dichloro-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 7-chloro-2-(6-methoxypyridin-3-yl)-N,N,9-trimethyl-9H-pyrimido[4,5-b]indole-4-carboxamide
  参考文献：
  名称：

  1H-Pyrimido[4,5-b]indole derivatives, their preparation and therapeutic use

  摘要：

  这项发明涉及一般式(I)的化合物： 其中n、X、Y、R1和R2如本文所定义。该发明还涉及制备这些化合物以及它们的治疗用途的方法。

  公开号：

  US20080125410A1
• 作为产物：
  描述：

  6-氯烟酰胺 在 1,4-二氧六环 、 盐酸 、 甲醇 、 氯仿 、 三氯氧磷 作用下， 生成 6-甲氧基-3-吡啶甲脒
  参考文献：
  名称：

  393. 砜类化疗剂。第 V.2 部分：吡啶的 5-二取代衍生物

  摘要：

  DOI：

  10.1039/jr9480001939

文献信息

• HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION
  申请人：BARTOLOZZI Alessandra

  公开号：US20130196967A1

  公开（公告）日：2013-08-01

  The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R 1 -R 7 , A and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物： 或其药用可接受的盐，其中R1-R7、A和HET按本文定义。本发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和失调的方法，以及制备这些化合物和在这些过程中有用的中间体的方法。
• 1H-Pyrimido[4,5-b]indole Derivatives, Their Preparation and Therapeutic Use
  申请人：FROISSANT Jacques

  公开号：US20090215741A1

  公开（公告）日：2009-08-27

  The disclosure concerns compounds of general formula (I): wherein n, X, Y, R 1 and R 2 are as defined herein. The disclosure also concerns a method for preparing the compounds and their therapeutic use.

  本公开涉及一般式（I）的化合物：其中n，X，Y，R1和R2的定义如本文所述。本公开还涉及制备这些化合物的方法以及它们的治疗用途。
• Novel nicotinamide analog as inhibitor of nicotinamide N-methyltransferase
  作者：Sven Ruf、Mahanandeesha Siddappa Hallur、Nisha K. Anchan、Indu N. Swamy、Karthikai Raj Murugesan、Sayantani Sarkar、Lokesh Kananti Narasimhulu、V.P. Rama Kishore Putta、Shama Shaik、Devaraj Venkatapura Chandrasekar、Vishal Subhash Mane、Sanjay Venkatachalapathi Kadnur、Juluri Suresh、Ravi Kanth Bhamidipati、Manvi Singh、Raghunadha Reddy Burri、Rajendra Kristam、Herman Schreuder、Joerg Czech、Christine Rudolph、Alexander Marker、Thomas Langer、Ramesh Mullangi、Takeshi Yura、Ramachandraiah Gosu、Aimo Kannt、Saravanakumar Dhakshinamoorthy、Sridharan Rajagopal

  DOI：10.1016/j.bmcl.2018.01.058

  日期：2018.3

  Nicotinamide N-methyltransferase (NNMT) has been linked to obesity and diabetes. We have identified a novel nicotinamide (NA) analog, compound 12 that inhibited NNMT enzymatic activity and reduced the formation of 1-methyl-nicotinamide (MNA), the primary metabolite of NA by ∼80% at 2 h when dosed in mice orally at 50 mg/kg.
• Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases
  作者：Clark A. Sehon、Gren Z. Wang、Andrew Q. Viet、Krista B. Goodman、Sarah E. Dowdell、Patricia A. Elkins、Simon F. Semus、Christopher Evans、Larry J. Jolivette、Robert B. Kirkpatrick、Edward Dul、Sanjay S. Khandekar、Tracey Yi、Lois L. Wright、Gary K. Smith、David J. Behm、Ross Bentley、Christopher P. Doe、Erding Hu、Dennis Lee

  DOI：10.1021/jm8005096

  日期：2008.11.13

  Recent studies using known Rho-associated kinase isoform 1 (ROCK1) inhibitors along with cellular and molecular biology data have revealed a pivotal role of this enzyme in many aspects of cardiovascular function. Here we report a series of ROCK 1 inhibitors which were originally derived from a dihydropyrimidinone core 1. Our efforts focused oil the optimization of dihydropyrimidine 2. which resulted in the identification of a series of dihydropyrimidines with improved pharmacokinetics and P450 properties.
• NOVEL COMPOUNDS
  申请人：Astra Pharmaceuticals Limited

  公开号：EP0915879A1

  公开（公告）日：1999-05-19